ING Group’s Enanta Pharmaceuticals ENTA Stock Holding History

ING Group’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-91,000	Closed	-$3.27M	–	841
2017 Q2	$3.27M	Buy	+91,000	New	+$2.91M	0.06%	166

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

ING Group's ENTA Position: Q3 2017 in Review

ING Group sold out of Enanta Pharmaceuticals (ENTA) in Q3 2017, closing a stake of 91,000 shares — an estimated $3.27M sold.

ING Group first reported a position in ENTA in Q2 2017 and held it in 1 quarter. The position peaked at $3.27M in Q2 2017. 127 funds tracked by Wall St. Rank hold ENTA as of Q3 2017.

ING Group reported no remaining Enanta Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
ING Group sold 91,000 Enanta Pharmaceuticals shares in Q3 2017, an estimated $3.27M.
ING Group first reported a position in Enanta Pharmaceuticals in Q2 2017 and held it in 1 quarter.
ING Group's Enanta Pharmaceuticals position peaked at $3.27M in Q2 2017.
127 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2017.

Based on ING Group's 13F filing for Q3 2017, filed 8 Nov 2017.